Cargando…
Dabigatran and apolipoprotein B
Autor principal: | ten Cate, Hugo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717405/ https://www.ncbi.nlm.nih.gov/pubmed/26567229 http://dx.doi.org/10.1136/heartjnl-2015-308575 |
Ejemplares similares
-
Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs
por: Honickel, M, et al.
Publicado: (2014) -
Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011) -
Volume replacement strategies do not impair the binding of dabigatran to idarucizumab: Porcine model of hemodilution
por: Grottke, Oliver, et al.
Publicado: (2019) -
Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
por: Henskens, Yvonne M. C., et al.
Publicado: (2018) -
New oral anticoagulants: discussion on monitoring and adherence should start now!
por: ten Cate, Hugo
Publicado: (2013)